Intravitreal injection of methotrexate in an experimental rabbit model: Determination of pharmacokinetics

Indian Journal of Ophthalmology

Volumn 59, Issue 3, 2011, Pages 197-200

  Ozkan, Ebru ^a   Ozcan, Altan ^a   Alparslan, Nazan ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Intravitreal injection; methotrexate; pharmacokinetics

Indexed keywords

METHOTREXATE;

ANIMAL; ARTICLE; CHEMISTRY; FEMALE; HALF LIFE TIME; INTRAVITREAL DRUG ADMINISTRATION; MALE; METABOLISM; OSMOLARITY; RABBIT; TISSUE DISTRIBUTION; VITREOUS BODY;

ANIMALS; FEMALE; HALF-LIFE; INTRAVITREAL INJECTIONS; MALE; METHOTREXATE; OSMOLAR CONCENTRATION; RABBITS; TISSUE DISTRIBUTION; VITREOUS BODY;

EID: 79957579845     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.81026     Document Type: Article

References (19)

1. Benet ZL. Pharmacokinetics: Absorption, distribution & elimination. In: Katzung BG, editor. Basic & Clinical Pharmacology. Norwalk: Prentice-Hall Int. Inc; 1992. p. 35-48.
2. Silvana G, Ciraci L, Santorsola D. Primary central nervous system lymphoma presenting as bilateral uveitis in an immunocompetent hepatitis C virus+ patient: A case report. Cases J 2009;2:152.
3. Lee EJ, Kim TW, Heo JW, Yu HG, Chung H. Natural killer/T-cell lymphoma of nasal type with intraocular involvement: Case report. Eur J Ophthalmol 2010;20:215-7.
4. Pe'er J, Hochberg FH, Foster CS. Clinical review: Treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm 2009;17:299-306.
5. Itty S, Olson JH, O'Connell DJ, Pulido JS. Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and/or radiotherapy. Retina 2009;29:415-6.
6. Kaufman PL, Gabelt BT. Aqueous humor hydrodynamics. In: Alm A, Kaufman PL, editors. Adler's Physiology of the Eye. St. Louis: Mosby; 2003. p. 237-92.
7. Andersen HL. Vitreous. In: Alm A, Kaufman PL, editors. Adler's Physiology of the Eye. St. Louis: Mosby; 2003. p. 293-318.
8. de Smet MD, Vancs VS, Kohler D, Solomon D. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 1999;83:448-51. (Pubitemid 29161187)
9. de Smet MD, Vancs VS, Kohler D, Smith J, Wittes R, Nussenblatt RB. Intraocular levels of methotrexate after intravenous administration. Am J Ophtalmol 1996;121:442-4. (Pubitemid 26113289)
10. Doolittle ND, Miner ME, Hall WA. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of the patients with malignant brain tumors. Cancer 2000;88:637-47. (Pubitemid 30056941)
11. Kraemer DF, Fortin D, Neuwelt EA. Chemotherapeutic dose intensification for treatment of malignant brain tumours: Recent developments and future directions. Curr Neurol Neurosci Rep 2002;2:216-24.
12. Henson JW, Yong T, Batchelor T. Intraocular methotrexate level after high dose intravenous infusion. T Clin Oncol 1999;17:132-9.
13. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997;115:1152-6. (Pubitemid 27387951)
14. Velez G, Boldt HC, Whitcup SM, Nussenblatt RB, Robinson MR. Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma. Ophthalmic Surg Lasers 2002;33:329-33.
15. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109:1709-16. (Pubitemid 35012013)
16. Heibig H, Cerny T, de Smet MD. Intravitreal chemotherapy for intraocular lymphoma. Ophthalmology 2003;100:145-9. (Pubitemid 36723509)
17. National Cancer Institute, National Institutes of Health. 1999.
18. Velez G, Yuan P, Sung C, Tansey G, Reed GF, Chan CC, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol 2001;119:1518-24. (Pubitemid 32963258)
19. Urtti A, Salminen L. Animal Pharmacokinetic Studies. In: Mitra AK, editor. Ophthalmic drug delivery system. New York: Marcel Dekker Inc.; 1993 p. 121-36.